Heartflow will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2025.
Quiver AI Summary
Heartflow, Inc., a leader in AI technology for coronary artery disease, announced that its management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:30 p.m. PT. The event will be available live and archived on the Heartflow website. Heartflow's innovations are reshaping cardiovascular care through advanced AI and a vast coronary imaging dataset, having been adopted by over 1,400 institutions worldwide. With support from leading cardiology organizations and extensive clinical validation, Heartflow's technology allows for accurate and timely diagnosis and management of coronary artery disease. The Heartflow One platform converts coronary CTA images into detailed 3D heart models, enabling precise insights into plaque characteristics and blood flow effects, all while adhering to rigorous compliance standards for data security and patient integrity.
Potential Positives
- Heartflow's participation in a fireside chat at a prominent healthcare conference enhances its visibility and credibility within the industry.
- The company's technology is supported by extensive clinical validation, with over 600 peer-reviewed publications, reinforcing its reputation as a leader in AI for coronary artery disease.
- Heartflow's solutions have been adopted by over 1,400 institutions globally, indicating strong market presence and demand for its innovative offerings.
- The mention of compliance with leading international standards ensures stakeholders of the company's commitment to quality and patient data integrity.
Potential Negatives
- None
FAQ
What is the date and time of the Heartflow fireside chat?
The Heartflow fireside chat is scheduled for December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET.
Where can I watch the Heartflow fireside chat?
The fireside chat will be available live and archived on the Investor Relations section of Heartflow's website.
What technology does Heartflow use for cardiovascular care?
Heartflow employs clinically-proven AI technology and utilizes the world’s largest coronary imaging dataset to enhance cardiovascular care.
How many institutions globally have adopted Heartflow’s technology?
More than 1,400 institutions globally have adopted Heartflow's technology for managing coronary artery disease.
What standards does Heartflow meet for data security and compliance?
Heartflow meets international standards including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001 for data security and compliance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HTFL Hedge Fund Activity
We have seen 83 institutional investors add shares of $HTFL stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 12,448,158 shares (+inf%) to their portfolio in Q3 2025, for an estimated $419,004,998
- WELLINGTON MANAGEMENT GROUP LLP added 4,880,064 shares (+inf%) to their portfolio in Q3 2025, for an estimated $164,262,954
- FMR LLC added 4,730,234 shares (+inf%) to their portfolio in Q3 2025, for an estimated $159,219,676
- BAILLIE GIFFORD & CO added 3,005,998 shares (+inf%) to their portfolio in Q3 2025, for an estimated $101,181,892
- SCHUSTERMAN INTERESTS, LLC added 1,939,201 shares (+inf%) to their portfolio in Q3 2025, for an estimated $65,273,505
- VANGUARD GROUP INC added 1,451,913 shares (+inf%) to their portfolio in Q3 2025, for an estimated $48,871,391
- CAPITAL INTERNATIONAL INVESTORS added 1,297,423 shares (+inf%) to their portfolio in Q3 2025, for an estimated $43,671,258
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HTFL Analyst Ratings
Wall Street analysts have issued reports on $HTFL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/13/2025
- Stifel issued a "Buy" rating on 11/13/2025
- Canaccord Genuity issued a "Buy" rating on 11/13/2025
- Piper Sandler issued a "Overweight" rating on 09/02/2025
To track analyst ratings and price targets for $HTFL, check out Quiver Quantitative's $HTFL forecast page.
$HTFL Price Targets
Multiple analysts have issued price targets for $HTFL recently. We have seen 4 analysts offer price targets for $HTFL in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Rick Wise from Stifel set a target price of $40.0 on 11/13/2025
- Robbie Marcus from JP Morgan set a target price of $40.0 on 11/13/2025
- William Plovanic from Canaccord Genuity set a target price of $40.0 on 11/13/2025
- Matt OBrien from Piper Sandler set a target price of $38.0 on 09/02/2025
Full Release
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37 th Annual Healthcare Conference. The fireside chat will take place on Wednesday, December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET.
A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com .
About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by American College of Cardiology and American Heart Association (ACC/AHA) guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide. Key benefits include:
- Proprietary data pipeline: Built from more than 110 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
- Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%.
- Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
- Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.
About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The
Heartflow One
platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at
heartflow.com
.
Investor Contact
Nick Laudico
[email protected]
Media Contact
Elliot Levy
[email protected]
